Different strains of cannabinoids and terpenes are effective at treating different conditions. A cannabis product that is optimal for one individual may not be suitable for another person because of variables including genetics, individual medical conditions and drug-drug interactions.
Reducing trial and error side effects from the use and prescribing of cannabis can occur by knowing your drug metabolism tendencies toward THC and CBD. Completing such a pharmacogenetics test will not only provide you and your prescriber this valuable knowledge but also inform you as to how cannabis will interact with other drugs that you consume, including alcohol and caffeine. Genetic testing, done with a simple cheek swab, can also offer insights about cannabis efficacy toward certain health conditions.
For certain mental health conditions and symptoms, understanding reasons why you might be experiencing them may be helpful to you and your health practitioners. It may be aggravated by a neurotransmitter or hormonal imbalance. These levels can be measured with a simple urine and saliva test, respectively. Once known, there are other prescriptions of natural health products and/or hormone replacement which may be helpful as an adjunct or alternative to cannabis use.
Each person breaks down certain ‘chemicals’ in their unique way based on their genetics and this chemical’s reaction to other substances. Our DNA test focuses on certain pathways of a specific drug without factoring its interactions with other drugs and/or foods.
A person who metabolizes THC poorly will take longer to clear THC from his or her system. Upon consuming a given dose of THC, a poor THC metabolizer will be subjected to the effects of THC longer than will a normal THC metabolizer.
A person who metabolizes CBD poorly will take longer to clear CBD from his or her system. Upon consuming a given dose of CBD, a poor CBD metabolizer will be subjected to the effects of CBD longer than will a normal CBD metabolizer.
DRUG INTERACTIONS AND ADDICTION
The endocannabinoid system (ECS), which is the main pathway through which some drugs exert their physiological effect(s), is known to play a role in the biology of addiction. Scientific studies have shown that individuals who possess certain genetic risk factors can become chemically more dependent on THC and Alcohol. Caffeine will also have a drug-drug interaction effect with the use of THC.
Scientific studies have shown that individuals who possess certain genetic risk factors can become chemically dependent on THC. This trait would suggest that such persons refrain from using THC.
The endocannabinoid system (ECS) plays a role in the onset and continuance of alcohol dependency. Hence, individuals who consume both THC and alcohol place themselves at increased risk for becoming addicted to either substance, or both substances. Studies have shown that THC can be addictive in genetically susceptible individuals; in contrast, CBD is nonaddictive and has been demonstrated to be effective at weening people off of certain types of drugs.
A recent clinical trial revealed that coffee consumption affects the endocannabinoid pathway. Scientific studies show that at low doses (1 mg/kg), the activity of caffeine inhibits the effects of THC. However, at high doses (3 mg/kg), the activity of caffeine reinforces the action of THC. For reference, a TALL Starbucks Branded Coffee contains 260 mg of caffeine. A person who is a slow caffeine metabolizer will take longer to clear caffeine from his or her system compared to a person who is a rapid caffeine metabolizer which impact longer, the effects of THC.
Tetrahydrocannabinol (THC), which is the primary psychoactive component of cannabis, has been shown to elicit both therapeutic benefits and adverse effects in people. Cannabidiol (CBD) is a major non-psychoactive component of cannabis that has analgesic, neuroprotective, anticonvulsant, antiemetic, antispasmodic and anti-inflammatory properties.
There are known genetic predispositions to certain physical and emotional health conditions which are impacted by the use of THC and CBD.
Individuals with increased pain sensitivity tend to have lower pain thresholds than the average person. Scientific studies have demonstrated that opioid-based analgesics tend to be less effective at alleviating discomfort in such individuals and can also have serious drawbacks including addiction. Because there is substantial evidence to indicate that cannabis is a relatively safe and effective treatment for chronic pain in adults, cannabinoids may represent a viable alternative to opiate-based pain control.
A common sleep disorder in which people have difficulty initiating and/or maintaining sleep and also tend to awaken prematurely. Research has shown that a person’s genetic makeup can contribute to their risk for developing insomnia. Cannabidiol (CBD), one of the non-psychoactive components of cannabis, has been reported to be a potential therapeutic for insomnia. It has also been suggested that some terpenoids found in cannabis, may prove useful for the treatment of insomnia due to their analgesic, anti-anxiety, and sedative qualities.
People with an extreme eating behaviour tend to manifest one or both of the following behaviours: 1) direct eating disinhibition and 2) eating restraint. Direct eating disinhibition, which is the loss of self-control during meals, is characterized by over-eating and weight gain. Eating restraint, on the other hand, is a behaviour in which one exercises strict control over one’s eating habits. Individuals who display eating restraint tend to either lose weight or maintain a stable weight. Some cannaboids have been shown to be effective in modulating eating behaviours.